Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Parra-Lara, Luis Gabriel, Martínez-Arboleda, Juan José, Rosso, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2020
Materias:
SARS CoV-2 Dispatches
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328586/
https://www.ncbi.nlm.nih.gov/pubmed/32622008
http://dx.doi.org/10.1016/j.jgar.2020.06.016
_version_ 1783552753610522624
author Parra-Lara, Luis Gabriel
Martínez-Arboleda, Juan José
Rosso, Fernando
author_facet Parra-Lara, Luis Gabriel
Martínez-Arboleda, Juan José
Rosso, Fernando
author_sort Parra-Lara, Luis Gabriel
collection PubMed
description • Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects. • Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.
format Online
Article
Text
id pubmed-7328586
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-73285862020-07-01 Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going Parra-Lara, Luis Gabriel Martínez-Arboleda, Juan José Rosso, Fernando J Glob Antimicrob Resist SARS CoV-2 Dispatches • Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects. • Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19. The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2020-09 2020-07-01 /pmc/articles/PMC7328586/ /pubmed/32622008 http://dx.doi.org/10.1016/j.jgar.2020.06.016 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle SARS CoV-2 Dispatches
Parra-Lara, Luis Gabriel
Martínez-Arboleda, Juan José
Rosso, Fernando
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
title Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
title_full Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
title_fullStr Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
title_full_unstemmed Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
title_short Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
title_sort azithromycin and sars-cov-2 infection: where we are now and where we are going
topic SARS CoV-2 Dispatches
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328586/
https://www.ncbi.nlm.nih.gov/pubmed/32622008
http://dx.doi.org/10.1016/j.jgar.2020.06.016
work_keys_str_mv AT parralaraluisgabriel azithromycinandsarscov2infectionwherewearenowandwherewearegoing
AT martinezarboledajuanjose azithromycinandsarscov2infectionwherewearenowandwherewearegoing
AT rossofernando azithromycinandsarscov2infectionwherewearenowandwherewearegoing

Ejemplares similares